Business
Avidity Biosciences to Host Virtual Investor and Analyst Event on May 19, 2021
Program to feature panel discussion with Drs. Phillip Zamore, UMASS, and Steven Dowdy UCSD, preeminent leaders in RNA therapeutics LA JOLLA, Calif., May 3,
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"Program to feature panel discussion with Drs. Phillip Zamore, UMASS, and Steven Dowdy UCSD, preeminent leaders in RNA therapeutics\n\n\nLA JOLLA, Calif., May 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it will host a virtual investor and analyst event focused on the company's AOC platform on Wednesday, May 19, 2021, from 8:00 a.m. to 10:00 a.m. PT/11:00 a.m. to 1:00 p.m. ET. This event is the first in a series of investor and analyst events that the company plans to host in 2021. \n\n \n \n \n \n \n \n\n \nThe May 19th event will feature a panel discussion with Phillip D. Zamore, Ph.D., Chair of the RNA Therapeutics Institute at UMASS, Steven F. Dowdy, Ph.D., Professor of Cellular and Molecular Medicine at UCSD, and Art Levin, Ph.D., Avidity's Chief Scientific Officer. The Avidity management team and Drs. Zamore and Dowdy will host a question and answer session following the panel. \nThe event will also feature a presentation from Dr. Levin who will provide an overview of the company's AOC platform and the translation of the platform into a pipeline of programs.\nBackground on Drs. Zamore and Dowdy:\nPhillip D. Zamore, Ph.D., the Gretchen Stone Cook Professor of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Investigator of the Howard Hughes Medical Institute, is Chair of the RNA Therapeutics Institute, which was established at the University of Massachusetts Medical School in 2009. He has a long history in RNA-targeting therapeutics and has been associated with the leading companies in the field. Dr. Zamore received his A.B. and Ph.D. degrees in Biochemistry and Molecular Biology from Harvard University. He then pursued postdoctoral studies at MIT and the Whitehead Institute for Biomedical Research.\nSteven F. Dowdy, Ph.D., is a professor in the Department of Cellular & Molecular Medicine at the University of California San Diego School of Medicine. His research focuses on the delivery of novel therapeutics, especially RNAi therapies, into cells. He has been involved in multiple RNA biotech startups and currently sits on five Scientific Advisory Boards. Dr. Dowdy received his Ph.D. in Molecular Genetics from the Univers...